Part-Time

Registered Nurse Home Health

Posted on 8/18/2026

Deadline 7/28/27
Enhabit

Enhabit

1-10 employees

Advises and builds healthier, efficient homes

No salary listed

Murfreesboro, TN, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Patient Care

Get referred to Enhabit

See people who can refer or advise you

Requirements
  • Be currently licensed as a Registered Nurse in the state of employment.
  • Demonstrate knowledge and skill in current nursing practice.
  • Possess a valid state driver's license and automobile liability insurance.
Responsibilities
  • Perform visits and complete coordination of client care.
  • Serve as the point of contact for all disciplines involved in providing care to patients.
  • Oversee the frequency of visits for the episode.
  • Consult as needed with the physician and the office, providing details about patient care.
  • Perform accurate OASIS collection.
  • Ensure the medication profile remains current.
  • Ensure lab values are reported to the physician in a timely manner.
  • Attend weekly case conferences and monthly case manager meetings.
Desired Qualifications
  • A minimum of one year of clinical experience.

What Enhabit does: Enhabit helps homeowners, utilities, and local governments create better living spaces that are efficient, healthy, and safe. They combine hands-on field work with practical advice to improve homes and communities. How its products work: The company carries out on-site projects to upgrade efficiency, safety, and healthy living features, while also providing guidance and design solutions to meet local needs. How it is different from competitors: Enhabit emphasizes social impact and collaborative work with multiple stakeholders (homeowners, utilities, and governments), delivering end-to-end services from assessment and planning to hands-on implementation. What its goal is: to build strong, thriving, and equitable communities by making everyday living spaces better for everyone.

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

Portland, Oregon

Founded

2009

Get referred to Enhabit

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 1.9% to $264.8 million, with hospice up 6.2%.
  • Management planned nine to twelve hospice de novos and $25–$50 million acquisitions in 2026.
  • The May 2026 go-private deal gives Kinderhook flexibility to fund growth beyond public markets.

What critics are saying

  • CMS reimbursement drives nearly all revenue; a 2026 rule shift hits margins immediately.
  • Kinderhook ownership and $428.6 million debt pressure cost cuts, restructurings, and staffing.
  • Failure to integrate de novos and acquisitions destroys cash flow and forces a Chapter 11.

What makes Enhabit unique

  • Kinderhook completed Enhabit’s $1.1 billion buyout on May 15, 2026.
  • Enhabit operates 249 home health and 117 hospice locations across 34 states.
  • Its Medicare and Medicare Advantage mix supplies 89.7% of revenue, creating payer scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Flexible Spending Accounts

Paid Vacation

Performance Bonus

Professional Development Budget

Company News

Yahoo Finance
Mar 5th, 2026
Enhabit matches Q4 earnings estimates, shares surge 47.5% this year

Enhabit, a provider of home health and hospice services, reported fourth-quarter earnings of $0.14 per share, matching the Zacks Consensus Estimate. This represents an improvement from $0.04 per share a year earlier and marks the fourth consecutive quarter the company has met or exceeded earnings expectations. Revenues reached $270.4 million for the quarter ended December 2025, surpassing consensus estimates by 0.40% and up from $258.2 million in the prior year. The company has topped revenue estimates in two of the last four quarters. Enhabit shares have gained 47.5% year-to-date, significantly outperforming the S&P 500's 0.4% decline. The stock currently carries a Zacks Rank of 2 (Buy), suggesting continued outperformance in the near term.